Biopeutics co., Ltd - des

By: Biopeutics  05/12/2011

WhenCharles Dotter first described a metal coil that could hold the artery open after angioplasty, this was the birth of the concept of a coronary-artery stent. However, it took 24 more years before could be used on the ischemic heart patients. Nowadays most patients routinely undergoing angioplasty have stents inserted as part of the interventional procedure. The popularity of stents is based on the recognition that stenting results in an immediately improved angiographic outcome.

Ou r goal is to develop a new generation of Drug Eluting Stent that will retard or stop restenosis, prevent platelet aggregation and adhesion, reduce vascular inflammation, promote rapid endothelial cell attachment and function within the lumen of the vessel and stent (a process called endothelialization) and finally promote the release of VGEF which stimulates new blood vessels formations (neoangiogenesis). The development of ALP-S1 is based on its pharmaceutical features to promote new blood-vessel generation in the heart muscle.  ALP-S1 has shown very promising results, with excellent reendothelialization and anti-proliferation characteristics in our in-vitro studies. We are currently conducting animal trials  and plan to have human trials in 2009.

Other products and services from Biopeutics


Biopeutics co., Ltd - products

Biopeutics is currently focusing on developing treatments for chronic heart failure, since this is one of the most challenging diseases, with poor prognosis in its advanced stage. Biopeutics currently has three clinical-stage products with a further one in animal-testing stage and also has two new delivery methods in our R&D pipeline.


Biopeutics co., Ltd - papeilin

Patients awaiting cardiac transplantation often suffer from severe dyspnea and extreme fatigue at rest despite optimized treatment with oral medications, making the use of continuous intravenous drug therapy necessary for circulatory support and to prolong survival to transplant.